Healthcare Industry News: Invatec
News Release - September 21, 2009
Invatec Launches the Maris Plus Self-Expanding Peripheral Stent System at CIRSE 2009Greater Visibility and Flexibility for the Treatment of PAD in the Iliac Region
LISBON, Portugal, Sept. 21--(HSMN NewsFeed)--Invatec, a comprehensive innovator of interventional products, today launched their latest self-expanding peripheral stent system, Maris Plus. The Maris Plus stent has a “lesion-specific” design with larger sizes to meet the clinical requirements of the iliac region. The Maris Plus becomes the sixth stent platform now marketed by Invatec for the treatment of Peripheral Arterial Disease (PAD), greatly optimizing visibility, flexibility and ease of use for the physician.
“At Invatec we pride ourselves on our ability to continually develop lesion specific solutions for Cardiovascular Arterial and Venous Disease. With the Maris Plus, we have created a novel, self-expanding stent platform specifically designed for the Iliac artery,” said Stefan Widensohler and Andrea Venturelli, co-founders of Invatec. The Maris Plus is available in a 30 – 100 mm length with 9.0 – 12.0 mm diameter, meeting the variable needs of the iliac region. The distinct stent geometry allows for increased stability in the hip, yet it remains the most flexible stent on the market. Additionally, larger and fully integrated tantalum markers greatly enhance visibility for the physician.
Headquartered in Italy and with manufacturing in Italy and Switzerland, Invatec is one of the world’s fastest growing companies in the design, development and production of interventional cardiology and peripheral vascular products for the treatment of coronary and peripheral arterial disease. Driven by research and technology, Invatec actively collaborates with physicians and centres of excellence to develop products that will improve life expectancy and quality of life for patients. Vertically integrated, Invatec also has the in-house ability to design, develop, manufacture and assemble its entire product offering from raw materials. As a result, the company has one of the largest therapeutic catheter product lines in the world, including 9 stent platforms, 6 angioplasty balloon platforms, 3 drug-eluting balloon platforms and accessory devices, now sold in over 70 countries.
Dedicated to "making ideas come alive," the company was founded in 1996 by Andrea Venturelli and Stefan Widensohler, and has grown to almost 1,000 employees. For more information, visit www.Invatec.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.